To our knowledge, this is the first randomized clinical trial demonstrating an isotoxic improvement in prostate cancer control outcomes with intensification of SRT informed by PSMA-PET in men who present with BCR after RP, in a modern cohort with prevalent use of adjuvant HT. Here, FOLH1 is linked to prostate cancer.